These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38498139)

  • 1. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
    Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Carter K; Lippe R; Photowala H; Drogaris L; Soliman AM; Chen M; Padilla B; Behrens F
    Rheumatol Ther; 2024 Jun; 11(3):617-632. PubMed ID: 38498141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Lu W; Wang Z; Soliman AM; Eldred A; Padilla B; Kivitz A
    Rheumatology (Oxford); 2023 Jun; 62(6):2122-2129. PubMed ID: 36282537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Alperovich G; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Kivitz A
    Ann Rheum Dis; 2022 Mar; 81(3):351-358. PubMed ID: 34815219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Soliman AM; Eldred A; Barcomb L; Behrens F
    Rheumatology (Oxford); 2023 Jun; 62(6):2113-2121. PubMed ID: 36282530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Behrens F
    Ann Rheum Dis; 2022 Feb; 81(2):225-231. PubMed ID: 34911706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
    Merola JF; Armstrong A; Khattri S; Paek SY; Padilla B; Yue C; Photowala H; Kaplan B; Kristensen LE
    J Dermatolog Treat; 2024 Dec; 35(1):2342383. PubMed ID: 38632977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
    Mease PJ; Kellner H; Morita A; Kivitz AJ; Aslanyan S; Padula SJ; Topp AS; Eldred A; Behrens F; Papp KA
    Rheumatol Ther; 2022 Oct; 9(5):1361-1375. PubMed ID: 35931879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Oct; 11(5):1403-1412. PubMed ID: 39120849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; White D; Barcomb L; Lu W; Eldred A; Behrens F
    Rheumatology (Oxford); 2023 Feb; 62(2):629-637. PubMed ID: 35801915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials.
    Kwatra SG; Khattri S; Amin AZ; Ranza R; Kaplan B; Shi L; Padilla B; Soliman AM; McGonagle D
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1517-1530. PubMed ID: 38739215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
    Ogdie A; Merola JF; Mease PJ; Ritchlin CT; Scher JU; Lafferty KP; Chan D; Chakravarty SD; Langholff W; Wang Y; Choi O; Krol Y; Gottlieb AB
    BMC Rheumatol; 2024 May; 8(1):20. PubMed ID: 38773563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
    Kristensen LE; Soliman AM; Papp K; Barcomb L; Eldred A; Östör A
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
    Ritchlin CT; Coates LC; McInnes IB; Mease PJ; Merola JF; Tanaka Y; Asahina A; Gossec L; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Landewé RB
    Ann Rheum Dis; 2023 Nov; 82(11):1404-1414. PubMed ID: 37696588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM
    Rheumatol Ther; 2024 Oct; 11(5):1197-1215. PubMed ID: 39031276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ; Merola JF; Tanaka Y; Gossec L; McInnes IB; Ritchlin CT; Landewé RBM; Asahina A; Ink B; Heinrichs A; Bajracharya R; Shende V; Coarse J; Coates LC
    Rheumatol Ther; 2024 Oct; 11(5):1363-1382. PubMed ID: 39215949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.